A Phase II, Multicenter, Randomized, Double Masked, Active Comparator-Controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7200220 Administered Intravitreally in Patients With Diabetic Macular Edema
Latest Information Update: 09 Aug 2024
At a glance
- Drugs Vamikibart (Primary) ; Ranibizumab
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Sponsors Roche
- 01 Dec 2023 Status changed from recruiting to active, no longer recruiting.
- 16 Aug 2023 Planned End Date changed from 31 May 2025 to 17 Apr 2025.
- 16 Aug 2023 Planned primary completion date changed from 31 Dec 2024 to 3 Oct 2024.